[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BluntForceOpt Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1651613086602899457.png) BluntForceOptions [@BluntForceOpt](/creator/twitter/BluntForceOpt) on x XXX followers
Created: 2025-07-16 21:09:47 UTC

$SRPT As expected, co just dropped the official update after all the recent chatter. Strategic restructuring + ELEVIDYS label update now confirmed.

• XX% workforce reduction (~500 employees)
• $400M in projected annual cost savings
• Pipeline shift to high-impact siRNA assets
• ELEVIDYS will carry a black box warning (resolving FDA concerns for ambulant patients)
• Plan submitted to resume dosing for non-ambulant patients (new protocol under review)
• Q2 prelim revenue: $513M ($282M from Elevidys)

Co says move ensures long-term viability and sharpens focus on siRNA pipeline (FSHD, DM1, IPF, Huntington's, etc.)

Stock up ~35% AH on what looks like a well-received cleanup + reset. Cheers, and GLTA.

![](https://pbs.twimg.com/media/GwAhQXvaUAAO4-k.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945591718491165103/c:line.svg)

**Related Topics**
[savings](/topic/savings)
[$400m](/topic/$400m)
[chapter 11](/topic/chapter-11)
[$srpt](/topic/$srpt)
[sarepta therapeutics inc](/topic/sarepta-therapeutics-inc)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/BluntForceOpt/status/1945591718491165103)